Are surveillance procedures of clinical benefit for patients treated for ovarian cancer? A retrospective italian multicentric study

International Journal of Gynecological Cancer

Volumn 19, Issue 3, 2009, Pages 367-374

  Gadducci, Angiolo ^a   Fuso, Luca ^b   Cosio, Stefania ^a   Landoni, Fabio ^c   Maggino, Tiziano ^d   Perotto, Stefania ^b   Sartori, Enrico ^e   Testa, Antonia ^f   Galletto, Luciano ^g   Zola, Paolo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d Unit of Gynaecology and Obstetrics   (Italy)

^e UNIVERSITY OF BRESCIA   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g Unit of Gynecology and Obstetrics   (Italy)

Author keywords

CA 125; Computed tomography; Follow up; Ovarian cancer; Recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EXAMINATION; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; ITALY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; THORAX RADIOGRAPHY; TREATMENT FAILURE;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; DIAGNOSTIC IMAGING; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; POPULATION SURVEILLANCE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 68149164781     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a1cc02     Document Type: Article

References (44)

1. Heintz APM, Odicino F., Maisonneuve P., et al. Carcinoma of the ovary. Int J Gynecol Obstet. 2006;95:S161-S192.
2. Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol. 2007;25:2873-2883.
3. Tropé C., Kaern J. Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature. J Clin Oncol. 2007;25:2909-2920.
4. 32P). Ann Oncol. 1995;6:887-893.
5. Gadducci A., Sartori E., Maggino T., et al. Analysis of failures in patients with stage I ovarian cancer: an Italian multicenter study. Int J Gynecol Cancer. 1997;7:445-450.
6. Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol. 2006;33:S3-S11.
7. Gadducci A., Sartori E., Maggino T., et al. Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study. Gynecol Oncol. 1998;68:150-155.
8. Gadducci A., Cosio S., Conte PF, et al. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit Rev Oncol Hematol. 2005;55:153-166.
9. Ovarian cancer: screening, treatment, and follow-up. NIH Consens Statement. 1994;12:1-30.
10. Vaidya AP, Curtin JP. The follow-up of ovarian cancer. Semin Oncol. 2003;30:401-412.
11. von Georgi R., Schubert K., Grant P., et al. Post-therapy surveillance and after-care in ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2004;114:228-233.
12. Gadducci A., Cosio S., Zola P., et al. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Int J Gynecol Cancer. 2007;17:21-31.
13. Zola P., Fuso L., Mazzola S., et al. Follow-up strategies in gynecological oncology: searching appropriateness. Int J Gynecol Cancer. 2007;17:1186-1193.
14. Rustin GJS, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol. 1996;7:361-364.
15. Rustin GJ, Marples M., Nelstrop AE, et al. Use of CA 125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol. 2001;19:4054-4057.
16. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist. 2002;7:20-28.
17. Jacobs I., Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989;4:1-12.
18. Gadducci A., Cosio S., Carpi A., et al. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother. 2004;58:24-38.
19. Kainz C., Prayer L., Gitsch G., et al. The diagnostic value of magnetic resonance imaging for the detection of tumor recurrence in patients with carcinoma of the ovaries. J Am Coll Surg. 1994;178:239-244.
20. Sugiyama T., Nishida T., Komai K., et al. Comparison of CA 125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancer. Int J Gynaecol Obstet. 1996;54:251-256.
21. Caserta D., Marci R., Porzio G., et al. Pelvic relapses in ovarian cancer. Role of CA-125, transvaginal ultrasound and color Doppler. Eur J Gynaecol Oncol. 2003;24:269-270.
22. Fehm T., Heller F., Kramer S., et al. Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients. Anticancer Res. 2005;25:1551-1554.
23. Grabiec M., Walentowicz M., Nowicki P. The value of FDG PET/CT, ultrasound and CT in diagnosing recurrent ovarian carcinoma. Ginekol Pol. 2006;77:746-752.
24. Ferrozzi F., Bova D., De Chiara F., et al. Thin-section CT follow-up of metastatic ovarian carcinoma correlation with levels of CA-125 marker and clinical history. Clin Imaging. 1998;22:364-370.
25. 18F) - FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol. 2000;10:761-767.
26. Sebastian S., Lee SI, Horowitz NS, et al. PET-CT vs. CTalone in ovarian cancer recurrence. Abdom Imaging. 2008;33:112-118.
27. Parmar MK, Ledermann JA, Colombo N., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099-2106.
28. Ozols RF. Gemcitabine and carboplatin in second-line ovarian cancer. Semin Oncol. 2005;32:S4-S8.
29. Herzog TJ, Pothuri B. Ovarian cancer: a focus on management of recurrent disease. Nat Clin Pract Oncol. 2006;3:604-611.
30. Bukowski RM, Ozols RF, Markman M. The management of recurrent ovarian cancer. Semin Oncol. 2007;34:S1-S15.
31. Buller RE, Skilling JS, Sood AK, et al. Field cancerization: why late "recurrent" ovarian cancer is not recurrent. Am J Obstet Gynecol. 1998;178:641-649.
32. Goonewardene TI, Hall MR, Rustin GJ. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol. 2007;8:813-821.
33. Cho SM, Ha HK, Byun JY, et al. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. AJR Am J Roentgenol. 2002;179:391-395.
34. Bristow RE, del Carmen MG, Pannu HK, et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined FDG-PET/CT. Gynecol Oncol. 2003;90: 519-528.
35. Pannu HK, Cohade C., Bristow RE, et al. FDG-PET-CT detection of abdominal recurrence of ovarian cancer: radiologic-surgical correlation. Abdom Imaging. 2004;29:398-403.
36. 18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging. 2007;34:480-486.
37. Zimny M., Siggelkow W., Schröder W., et al. 2-[Fluorine-18]-fluoro- 2-deoxy-D-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol. 2001;83:310-315.
38. Bristow RE, Simpkins F., Pannu HK, et al. Positron emission tomography for detecting clinically occult surgically resectable metastatic ovarian cancer. Gynecol Oncol. 2002;85:196-200.
39. 18F-FDG-PET/CT: an unusual finding. Cancer Imaging. 2006;6:20-23.
40. Simcock B., Neesham D., Quinn M., et al. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol. 2006;103:271-276.
41. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000;88:144-153.
42. Chi DS, McCaughty K., Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106:1933-1939.
43. Salani R., Santillan A., Zahurak ML, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer. 2007;109: 685-691.
44. Mangili G., Picchio M., Sironi S., et al. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging. 2007;34:658-666.